We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Immunoassay Used to Diagnose Acute Leukemia.

By LabMedica International staff writers
Posted on 05 Oct 2010
An immunofluorescence (IF) assay, using monoclonal antibodies, has been evaluated for the diagnosis of acute promyelocytic leukemia (APL), which is considered a medical emergency.

APL is a distinct subtype of acute myeloid leukemia (AML) characterized by a reciprocal translocation, and a high incidence of life-threatening coagulopathy. More...
As reverse transcription-polymerase chain reaction (RT-PCR) for the promyelocytic leukemia (PML) - retinoic acid receptor (RAR) alpha fusion oncoprotein is time consuming, there is a need for a rapid and accurate diagnostic test for APL.

A study was carried out at the All India Institute of Medical Sciences, (New Delhi, India), to evaluates the role of the monoclonal antibody, PG-M3, using immunofluorescence (IF) in the early diagnosis of APL. PG-M3 antibodies are specifically directed against a peptide sequence located in the amino-terminal region of the human PML protein. Thirty-six new untreated APL cases diagnosed with RT-PCR for PML-RAR alpha as the gold standard and 38 non-APL controls (28 non-APL AMLs and 10 non-leukemia samples) were evaluated by routine morphology and cytochemistry, RT-PCR, and IF using PG-M3 monoclonal antibody. The median age of APL patients was 35 years (range 9–75 years) and included 19 men and 17 women.

The IF assay, using the PG-M3 antibodies, takes two hours to perform. Of the 36 APL cases, 34 (94.4 %) showed a microgranular pattern of immunofluorescence (IF) and two cases (5.6%) showed speckled pattern indicating possible false negatives. Of 28 non-APL AML controls, 26 (92.9%) showed a speckled pattern and two (7.1%) cases showed microgranular pattern indicating false positives. IF was significantly superior compared with morphology alone for the diagnosis of APL. All 10 non-leukemic controls were correctly identified as negative for APL on both morphology and IF (speckled). There were no cases or controls, which could not be evaluated by IF. The study was published online on August 4, 2010 in the European Journal of Clinical Investigation.

The authors concluded that, PG-M3 antibodies could be used as a rapid, cheap, sensitive, and specific method to identify APL. It can be a useful adjunct for diagnosis of APL especially if facilities for RT-PCR are not available, particularly in resource-limited settings.

Related Links:

All India Institute of Medical Sciences




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.